The ULab Joint Laboratory was officially inaugurated at the recent seminar on strategies for innovative pharmaceutical companies expanding overseas.
The consortium includes the ULab Gaoyue Shanghai Joint Laboratory, ULab Seaknit Kobe Joint Laboratory, and ULab NJS Boston Joint Laboratory, aiming to connect China, the United States, and Japan, accelerating the international market entry of Chinese innovative drugs.
The ULab Joint Laboratory will provide preliminary consulting and resource-matching services for Chinese companies seeking to expand their innovative drug pipelines internationally. In addition to offering high-quality overseas CRO (Contract Research Organization) resources, it will assist domestic companies in finding suitable partners for business development (BD), including financing and mergers and acquisitions.
Shou Xiaoqi, general manager of Shanghai United Development Center, a key organizer of the ULab Joint Laboratory, stated: "Over the years, we have accumulated a wealth of overseas resources, primarily helping foreign-invested enterprises enter China. Now, we hope to use these overseas investment resources and channels to help Chinese companies expand abroad."
Located in Pudong, the innovative company Nulunjie Biotech focuses on developing new gene therapy drugs for neurological diseases using its proprietary cell technology. Dr. Zhu Chao, co-founder and CEO of Nulunjie, admitted that for small and medium-sized enterprises, financial support is crucial for drug development.
"The joint laboratory model is very timely for us. Although our technology is already at the forefront globally, financing is essential to truly enter the global market. Gaining favor in overseas capital markets would accelerate the transformation of our products and help us quickly capture the global market."
By mid-year, the ULab Joint Laboratory will also establish a presence in Europe, providing "full-chain" services for domestic companies entering the European market.
